MedPath

MRI Scan of patients implanted with MRI conditional Cardiac Rhythm Management system

Completed
Conditions
patients indicated for any one of the following: ICD / CRT-D / Pacemaker
Registration Number
CTRI/2017/05/008447
Lead Sponsor
St Jude Medical India Ltd
Brief Summary

This is a prospective, multi-center clinical study designed to confirm the safety and effectiveness of St. Jude Medical low voltage pacemakers, high voltage dual chamber ICDs, and CRT-Ds with various leads in an MRI environment.

Total of 119 subjects enrolled across 14 investigational sites. The total duration of the study is 14 months. All Subjects were followed for 1 month following the MRI scan.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
88
Inclusion Criteria
  • Eligible subjects will meet all of the following: • Are implanted with one of the following SJM device/lead combinations evaluated in this study for at least 60 days (can include patients with an eligible SJM lead for ≥ 60 days OR patients with a new eligible SJM pacemaker, ICD, or CRT device and eligible SJM lead implanted for at least 60 days: 1.
  • Accent MRIâ„¢, Assurity MRIâ„¢, Endurity MRIâ„¢, or Endurity pacemaker with Tendrilâ„¢ STS Model 2088 lead 2.
  • Accent MRIâ„¢, Assurity MRIâ„¢, Endurity MRIâ„¢, or Endurity pacemaker with IsoFlexâ„¢ Optim (Model 1944 or 1948) lead 3.
  • Ellipseâ„¢ VR/DR or Fortify Assura VR/DR ICD with Tendrilâ„¢ STS (Model 2088) or Tendril MRIâ„¢ and Durataâ„¢ or Optisureâ„¢ leads 4.
  • Quadra Assuraâ„¢ CRT-D with Tendrilâ„¢ STS (Model 2088), Durataâ„¢ or Optisureâ„¢, and Quartetâ„¢ Quadripolar leads • Are implanted with an eligible SJM pacemaker, ICD, or CRT-D device pectorally • Be willing to undergo an elective MRI scan without sedation.
  • Note: Antianxiety agents (e.g. minor tranquilizers, etc.) may be used as long as the subject can communicate with site personnel during the MRI scan • Be able to provide informed consent for study participation (legal guardian is NOT acceptable) • Be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.
Exclusion Criteria
  • Subjects will be excluded if they meet any of the following: • Have another existing active implanted medical device, e.g., neurostimulator, infusion pump, etc.
  • that has MR labeling that will not allow the MRI scans per this protocol to be completed.
  • • Have other non-MRI compatible device or material implanted o NOTE: MRI compatible knee replacements, hip replacements, stents, etc.
  • may be included as long as the labeling of these devices allow MRI scans conducted per this protocol o NOTE: MRI compatible mechanical, prosthetic, and bioprosthetic heart valves may be included as long as the labeling of these devices allow for MRI scans conducted per this protocol o NOTE: Non-removable dental implants may be included • Have a lead extender, adaptor, or capped/abandoned lead • Be unable to fit in MRI bore, i.e., subject will come into contact with the magnet façade inside the MRI bore.
  • • Are currently participating in a clinical investigation that includes an active treatment arm • Are pregnant or planning to become pregnant during the duration of the study • Have a life expectancy of less than 3 months due to any condition • Meet exclusion criteria per local law (e.g. age).

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Freedom from MRI scan-related complications: one month following the MRI scan.one month post MRI scan
Secondary Outcome Measures
NameTimeMethod
Proportion of subjects with a capture threshold increase of less than 0.5V at 0.5 ms from pre MRI scan to one month post MRI scanone month post MRI scan

Trial Locations

Locations (3)

Apollo Hospital, Chennai

🇮🇳

Chennai, TAMIL NADU, India

Care Hospital,

🇮🇳

Hyderabad, ANDHRA PRADESH, India

Fortis Escorts Heart Institute & Research Center

🇮🇳

Delhi, DELHI, India

Apollo Hospital, Chennai
🇮🇳Chennai, TAMIL NADU, India
Dr A M Karthigesan
Principal investigator
91-8939177087
drkarthigesan_am@apollohospitals.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.